UNITED LAB's Dupilumab Biosimilar Receives Clinical Trial Approval

Stock News04-22

UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained implied approval from the National Medical Products Administration for clinical trials of its dupilumab biosimilar for the treatment of atopic dermatitis. The application acceptance number is CXSL2600180.

Dupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody used to treat atopic dermatitis, particularly moderate-to-severe cases where topical treatments are ineffective or not recommended. The drug specifically binds to the interleukin-4 receptor alpha subunit (IL-4Rα), blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13). This action inhibits type 2 inflammatory responses, reduces the secretion of inflammation-related cytokines, lowers immunoglobulin E (IgE) levels, and improves skin and mucosal barrier function. It is currently a key targeted therapy for type 2 inflammatory diseases, including atopic dermatitis.

This approval marks another significant milestone in the company's innovative research and development efforts in the field of inflammatory and autoimmune diseases. Moving forward, UNITED LAB will continue to focus on the development of new products, with an emphasis on enhancing its competitiveness and innovation in the biopharmaceutical industry. This is expected to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110058142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110058142","market":"sh","top_or_hot":-1,"title":"UNITED LAB's Dupilumab Biosimilar Receives Clinical Trial Approval","media":"Stock News","content":"<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained implied approval from the National Medical Products Administration for clinical trials of its dupilumab biosimilar for the treatment of atopic dermatitis. The application acceptance number is CXSL2600180.</p>\n<p>Dupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody used to treat atopic dermatitis, particularly moderate-to-severe cases where topical treatments are ineffective or not recommended. The drug specifically binds to the interleukin-4 receptor alpha subunit (IL-4Rα), blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13). This action inhibits type 2 inflammatory responses, reduces the secretion of inflammation-related cytokines, lowers immunoglobulin E (IgE) levels, and improves skin and mucosal barrier function. It is currently a key targeted therapy for type 2 inflammatory diseases, including atopic dermatitis.</p>\n<p>This approval marks another significant milestone in the company's innovative research and development efforts in the field of inflammatory and autoimmune diseases. Moving forward, UNITED LAB will continue to focus on the development of new products, with an emphasis on enhancing its competitiveness and innovation in the biopharmaceutical industry. This is expected to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB's Dupilumab Biosimilar Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB's Dupilumab Biosimilar Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-22 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained implied approval from the National Medical Products Administration for clinical trials of its dupilumab biosimilar for the treatment of atopic dermatitis. The application acceptance number is CXSL2600180.</p>\n<p>Dupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody used to treat atopic dermatitis, particularly moderate-to-severe cases where topical treatments are ineffective or not recommended. The drug specifically binds to the interleukin-4 receptor alpha subunit (IL-4Rα), blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13). This action inhibits type 2 inflammatory responses, reduces the secretion of inflammation-related cytokines, lowers immunoglobulin E (IgE) levels, and improves skin and mucosal barrier function. It is currently a key targeted therapy for type 2 inflammatory diseases, including atopic dermatitis.</p>\n<p>This approval marks another significant milestone in the company's innovative research and development efforts in the field of inflammatory and autoimmune diseases. Moving forward, UNITED LAB will continue to focus on the development of new products, with an emphasis on enhancing its competitiveness and innovation in the biopharmaceutical industry. This is expected to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1110058142","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110058142","pubTimestamp":1776857018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained implied approval from the National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"联邦制药Dupilumab生物类似药获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Biopharmaceuticals Co., Ltd., has obtained implied approval from the National Medical Products Administration for clinical trials of its dupilumab biosimilar for the treatment of atopic dermatitis. The application acceptance number is CXSL2600180.\nDupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody used to treat atopic dermatitis, particularly moderate-to-severe cases where topical treatments are ineffective or not recommended. The drug specifically binds to the interleukin-4 receptor alpha subunit (IL-4Rα), blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13). This action inhibits type 2 inflammatory responses, reduces the secretion of inflammation-related cytokines, lowers immunoglobulin E (IgE) levels, and improves skin and mucosal barrier function. It is currently a key targeted therapy for type 2 inflammatory diseases, including atopic dermatitis.\nThis approval marks another significant milestone in the company's innovative research and development efforts in the field of inflammatory and autoimmune diseases. Moving forward, UNITED LAB will continue to focus on the development of new products, with an emphasis on enhancing its competitiveness and innovation in the biopharmaceutical industry. This is expected to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110058142","isCrawlerRequest":true}